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Viscoelastometry	guided	fresh	frozen	plasma	infusion	for	postpartum	haemorrhage:	an	
observational	study:	OBS2	
Concise	title:	Rotem	guided	FFP	infusion	for	PPH.	
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Summary	
Background	
Postpartum	haemorrhage	(PPH)	may	be	exacerbated	by	haemostatic	failure.		Based	on	data	from	
trauma	studies,	empirical	infusions	of	fresh	frozen	plasma	(FFP)	are	often	given	during	severe	PPH	if	
coagulation	tests	are	unavailable.	This	study	observed	a	cohort	of	women	with	moderate/severe	
PPH	in	whom	FFP	infusion	was	guided	by	the	use	of	viscoelastometric	point-of-care	testing	(VE-
POCT)	and	clinical	assessment.		
Methods	
Women	were	enrolled	into	this	observational	study	when	blood	loss	was	measured	or	suspected	to	
be	about	1000	mL.	If	Fibtem	A5	remained	>15	mm,	or	bleeding	stopped,	FFP	was	withheld.	If	Fibtem	
A5	was	≤15	mm	and	bleeding	ongoing	women	were	randomised	into	an	interventional	study	as	
previously	reported.	Clinical	and	laboratory	outcomes	were	recorded.		
Results	
The	study	recruited	605	women	and	98%	had	FFP	withheld.	The	median	(25
th
-75
th
	centile)	total	
blood	loss	was	1500	(1300-2000)	mL	with	300	(50-545)	mL	occurring	after	enrolment.	Total	blood	
loss	was	>2500	mL	in	40/605	(6.6%)	women.	RBCs	were	transfused	in	141/605	(23.3%)	cases	and	11	
(1.8%)	received	≥4	units.	At	least	one	invasive	procedure	was	performed	in	283/605	(46.8%)	women.	
Level	3	care	was	required	for	10/605	(1.7%)	women.	No	women	developed	clinically	significant	
haemostatic	impairment.	
Conclusions	
A	restrictive	use	of	FFP	guided	by	clinical	assessment	of	bleeding	and	VE-POCT	is	feasible	and	did	not	
result	in	clinically	significant	haemostatic	impairment.	Studies	should	compare	the	clinical	and	cost	
effectiveness	of	empirical	FFP	infusions,	according	to	current	guidelines,	with	a	targeted	use	of	FFP	
based	on	VE-POCT.	
	
Key	words:	Postpartum	haemorrhage;	fresh	frozen	plasma;	viscoelastometric	test,		
Trial	registration:	ISRCTN46295339	(http://www.isrctn.com/ISRCTN46295339),	EudraCT	2012-
005511-11	(https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005511-11)	
Introduction	
Postpartum	haemorrhage	(PPH)	is	precipitated	predominantly	by	obstetric	causes	but	may	be	
exacerbated	by	haemostatic	impairment.	Some	bleeds	resolve	before	clinically	significant	
coagulopathy	develops	whilst	others	are	associated	with	severe	haemostatic	impairment.	The	
likelihood	of	coagulopathy	depends	on	the	cause	and	size	of	the	bleed.
1-3
	The	Royal	College	of	
Obstetrics	and	Gynaecology	(RCOG)	defines	established	haemostatic	impairment	as	ongoing	
bleeding	associated	with	a	prothrombin	time	(PT)	or	activated	partial	thromboplastin	time	(aPTT)	
>1.5	times	normal	and	recommend	infusing	fresh	frozen	plasma	(FFP)	to	maintain	PT/aPTT	below	
this	ratio.
4
	Guidelines	recommend	maintaining	a	fibrinogen	>2	g	L
-1
	and,	if	bleeding	has	stopped,	no	
blood	product	replacement	is	required.
2;4
	
Haemostatic	impairment	may	evolve	rapidly	and	routine	laboratory	coagulation	tests	are	often	not	
available	soon	enough	to	be	clinically	useful.	Clinicians,	therefore,	may	not	know	whether	a	
coagulopathy	is	developing.
5
	This	has	led	to	guidelines	recommending	empirical	fixed-ratios	of	red	
blood	cells	(RBC)	and	FFP	to	manage	PPH.
2;4;6-8
	This	strategy	is	based	on	data	derived	from	trauma	
with	limited	evidence	in	PPH.
9-11
	The	haemostatic	system	at	term	is	hypercoagulant	compared	to	the	
healthy	non-pregnant	population
1;3
	and	trauma-induced-coagulopathy	differs	markedly	from	the	
coagulopathy	associated	with	PPH.
12;13
	It	may	be	inappropriate,	therefore,	to	extrapolate	treatment	
strategies	from	trauma	to	PPH.	Fixed-ratio	transfusion	may	result	in	unnecessary	transfusion	of	FFP	
and	be	associated	with	complications	such	as	transfusion	associated	circulatory	overload	and	allergic	
reactions.
12;14-16
	
During	PPH,	fibrinogen	falls	earlier	than	other	coagulation	factors
17
	suggesting	that	if	fibrinogen	is	
maintained	then	other	coagulation	factors	will	be	adequate.	A	viscoelastometric	point-of-care	test	
(VE-POCT),	Fibtem	A5	performed	on	the	Rotem®	machine,	is	a	surrogate	measure	of	fibrinogen	and	
results	are	available	within	10	minutes.	Fibtem	A5	correlates	with	laboratory	fibrinogen	during	PPH
18
	
and	is	predictive	of	progression	from	moderate	to	severe	PPH.
19
	
The	aim	of	the	study	was	to	investigate	a	cohort	of	women	experiencing	moderate	to	severe	PPH.	
Women	with	Fibtem	A5	≤15	mm	(Clauss	fibrinogen	about	3g/L)
18;19	
and	ongoing	bleeding	were	
eligible	to	be	randomised	to	the	interventional	part	of	the	study	comparing	the	effectiveness	of	
fibrinogen	concentrate	or	placebo.	The	randomised	women	showed	that,	if	plasma	fibrinogen	was	
>2	g/L	or	Fibtem	A5	>12	mm,	infusion	of	fibrinogen	concentrate	did	not	affect	outcomes.
20
	The	
protocol	instructed	that	for	women	in	whom	the	Fibtem	A5	was	>15	mm,	or	in	whom	bleeding	had	
stopped,	FFP	should	be	withheld.	These	women	are	reported	here.	
	
Methods	
This	was	an	observational	study	conducted	in	teaching	hospital	obstetric	units	and	formed	part	of	a	
multicentre	trial	to	randomise	women	to	fibrinogen	or	placebo.	The	protocol	is	published.
21
		Trial	
registration:	ISRCTN46295339	(http://www.isrctn.com/ISRCTN46295339),	EudraCT	2012-005511-11	
(https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005511-11).	The	study	was	
approved	by	Edinburgh,	Multicentre	Research	Ethics	Committee	(13/SS/0008).	
Women	age	≥18	year	and	≥24	weeks	gestation	experiencing	major	PPH	(measured	or	suspected	to	
be	about	1000	mL)	could	be	enrolled.	Women	were	excluded	if	they	declined	blood	transfusion,	had	
placenta	accreta	diagnosed	antenatally	or	there	was	clinical	suspicion	of	amniotic	fluid	embolus.
21
	
Women	received	written	information	in	their	maternity	notes.	Verbal	consent	to	participate	was	
sought	at	enrolment	and	confirmed	in	writing	once	the	woman	had	recovered.	At	study	entry	a	
Fibtem	was	performed	on	delivery	suite	and	samples	sent	to	the	laboratory	for	a	full	blood	count	
(FBC),	Clauss	fibrinogen,	PT	and	aPTT.	Blood	loss	was	estimated	gravimetrically	as	described.
22
	If	the	
A5	was	≤15	mm,	the	baby	delivered	and	bleeding	ongoing,	the	woman	was	randomised	to	fibrinogen	
concentrate	or	placebo.	If	the	A5	was	>15	mm	local	standard	treatment	for	PPH	was	given	except	
that	FFP	should	not	have	been	infused	(cryoprecipitate	infusion	was	not	excluded).	A	Fibtem	was	
repeated	after	each	additional	500	mL	blood	loss	or	for	clinical	concern	and	FFP	continued	to	be	
withheld	if	the	A5	remained	≥15	mm	or	if	the	bleeding	stopped	(Figure	1).		
Information	was	collected	electronically.	A	full	description	of	data	points	has	been	published.
21
	
Analysis	of	the	observational	group	reported	here	was	descriptive	and	no	hypotheses	were	tested,	
therefore,	a	sample	size	calculation	was	not	conducted.		Established	laboratory	haemostatic	failure	
was	defined	in	accordance	with	RCOG	guidelines	as	PT	or	aPTT	>1.5	times	the	midpoint	of	the	
normal	range	(in	this	study	≥16.5	sec	and	≥48	sec,	respectively)	or	a	fibrinogen	<2	g	L
-1
.
4
	Clinically	
significant	haemostatic	impairment	was	defined	as	established	laboratory	haemostatic	failure	
associated	with	continuing	bleeding.		Level	3	care	was	advanced	respiratory	support	or	receiving	2	
other	organs	support	(usually	renal	or	cardiac).		
Descriptive	summaries	of	maternal	characteristics	at	study	entry	by	cohort	(observational	or	
intervention)	were	performed	and	the	means	of	the	continuous	variables	were	compared	using			
Student’s	t-test	for	continuous	variables	(Mann-Whitney	for	non-normal	distributions)	and	
proportions	of	the	binary	variables	were	compared	using	the	χ2	test.		Analyses	were	performed	using	
SPSS	version	23	(IBM	SPSS	Inc,	Chicago,	USA).		
Results	
The	 observational	 study	 cohort	 comprised	 606	 women	 with	 moderate	 to	 severe	 PPH	 recruited	
between	29
th
	 June	2013	 and	26
th	
November	 2015	who	were	not	 eligible	 to	 be	 randomised	 to	 the	
interventional	 trial	 because	 either	 their	 Fibtem	 A5	 remained	 >15	 mm	 or	 bleeding	 stopped.	 One	
woman	 withdrew	 consent,	 therefore,	 605	 women	 are	 reported	 who	 were	 managed	 though	 the	
observational	arm	of	the	protocol	and	should	have	had	FFP	withheld	(Figure	2).	The	outcomes	of	the	
57	women	recruited	to	the	interventional	arm	are	reported	elsewhere.
20
	
Subject	characteristics	at	enrolment,	mode	of	delivery	and	cause	of	bleeding	are	shown	in	table	1,	
the	 enrolment	 characteristics	 of	 the	 women	 who	 were	 randomised	 are	 shown	 for	 comparison.	
Women	in	the	observational	group	had	smaller	bleeds	at	study	entry	and,	as	a	direct	consequence	of	
study	design,	had	higher	 fibrinogen	and	Fibtem	A5	 than	 the	 interventional	group	although	PT	and	
aPTT	were	similar.	
The	outcomes	of	women	in	the	observational	group	are	shown	in	table	2	and	the	interventional	
group	is	shown	for	comparison.	The	median	(25
th
	to	75
th
centile)	total	blood	loss	was	1500	(1300-
2000)	mL	with	300	(50-545)	mL	blood	loss	occurring	after	enrolment.	Total	blood	loss	was	>2500	mL	
in	40/605	(6.6%)	women.	RBCs	were	transfused	in	141/605	(23.3%)	women	and	11	(1.8%)	received	
≥4	units	RBCs.	At	least	one	invasive	procedure	was	performed	in	283/605	(46.8%)	cases,	most	
commonly	repair	of	perineal	trauma	(25.5%)	or	vaginal	packing	(13.2%).	Level	3	care	was	required	
for	10/605	(1.7%)	women.		
Fibtem	A5	was	≤15	mm	in	97/605	(15.7%)	women	at	some	time	during	the	observational	study.	The	
median	(25
th
	to	75
th
	centile)	blood	loss	after	the	A5	fell	to	≤15	mm	was	100	(0-335)	mL	indicating	
that	bleeding	was	rapidly	controlled	by	obstetric	intervention	in	most	cases.	To	investigate	whether	
withholding	FFP	may	have	influenced	outcomes,	women	who	developed	laboratory	evidence	of	
established	haemostatic	failure	(n=8)	(Table	3),	were	treated	with	FFP	contrary	to	the	protocol	
(n=12)	(Table	4),	admitted	to	ITU	(n=10)	(Table	4)	or	bled	>2500	mL	were	reviewed	in	detail.	Some	
women	appear	in	more	than	one	of	these	groups.	
	
	
Women	with	laboratory	tests	associated	with	established	haemostatic	failure	
The	longest	PT,	aPTT	and	lowest	fibrinogen	are	shown	in	Table	2.	Where	data	were	available,	3/537	
(0.6%)	had	a	PT	ratio	>1.5,	0/544	(0%)	had	an	aPTT	>1.5	and	6/544	(1.1%)	had	a	fibrinogen	<2	g	L
-
	at	
some	time	during	the	study.	Eight	women	developed	laboratory	evidence	of	established	haemostatic	
failure	as	defined	by	RCOG
4
	(Table	3),	these	women	had	a	median	(25
th
	to	75
th
	centile)	50	(0-280)	mL	
blood	loss	after	study	entry.	In	all	cases	bleeding	stopped	rapidly,	despite	the	abnormal	coagulation	
results,	following	obstetric	interventions	and	hence	did	not	fulfil	the	criteria	for	clinical	significant	
haemostatic	impairment.		
	
Women	who	received	FFP	or	were	admitted	to	level	3	care	
Twelve	women	(2.0%)	received	between	1-4	units	of	FFP	despite	this	being	contrary	to	the	protocol.	
Individual	details	of	coagulation	tests,	blood	products	received	and	outcomes	are	described	in	(Table	
4).	Ten/605	women	(1.7%)	were	admitted	to	level	3	care,	4	of	whom	received	FFP	and	one	
cryoprecipitate	(Table	4).	In	the	7	women	on	whom	data	were	available,	none	had	laboratory	
evidence	of	established	haemostatic	impairment	or	a	low	Fibtem.		
Women	with	a	total	measured	blood	loss	more	than	2500	mL	
Forty/605	(6.6%)	women	bled	>2500	mL.	Five	women	also	received	FFP	and	are	reported	in	detail	in	
table	4.	In	the	35	women	who	did	not	received	FFP	the	median	(25
th
	to	75
th
	centile,	range)	blood	loss	
was	3000	(2700-3000,	2530-5500)	mL	and	the	lowest	Fibtem	A5	was	19	(16-22,	10-34)	mm.	The	
lowest	laboratory	fibrinogen	was	known	for	32	and	was	3.4	(2.4-4.6,	2.3-6)	g/L.	None	of	the	woman,	
on	whom	data	were	available	(n=32),	had	laboratory	evidence	of	established	haemostatic	failure	at	
any	time	and	lowest	Fibtem	A5s	in	the	other	3	women	were	20,	22	and	34	mm.	In	total	24/35	
(68.6%)	received	RBCs	and	23/35	(65.7%)	women	had	between	1	and	4	invasive	procedures	to	
control	bleeding.	Five/35	(14.2%)	women	had	a	Fibtem	A5	≤15	mm	but	bleeding	stopped	soon	
afterwards	and	so	they	were	not	randomised.	One	woman	bled	an	additional	1500	mL	after	the	
Fibtem	A5	was	11	mm.	She	bled	a	total	of	3000	mL	in	25	minutes	due	to	uterine	atony	which	was	
controlled	with	an	intra-uterine	balloon.	The	Fibtem	A5	result	of	11	mm	was	available	about	10	
minutes	before	the	bleeding	stopped	and	hence	she	was	not	randomised,	she	received	4	units	of	
RBC	and	no	FFP.	
	
	
Discussion	
This	study	reports	on	a	cohort	of	women	with	moderate	to	severe	PPH	whose	blood	product	
management	was	stratified	according	to	the	criteria	of	ongoing	bleeding	and	Fibtem	A5.	Of	the	663	
women	recruited	into	the	OBS2	study,	including	both	the	randomised	and	observational	groups,	605	
(91.2%)	maintained	a	Fibtem	A5	>15	mm	or,	if	the	Fibtem	fell	below	15	mm,	the	bleeding	was	rapidly	
controlled	by	obstetric	intervention.	Despite	a	restrictive	use	of	FFP,	none	of	the	605	women	
reported	in	this	study	developed	clinically	significant	haemostatic	impairment,	defined	as	laboratory	
evidence	of	established	haemostatic	failure	associated	with	continuing	bleeding.	
A	lower	proportion	of	the	observational	group	had	a	placental	abruption	than	the	interventional	
group.	This	might	be	explained	because	abruption	is	known	to	be	associated	with	a	reduced	
fibrinogen	
1;23-25
	and	this	precipitated	randomisation.	In	contrast,	the	observational	group	had	a	
higher	proportion	of	bleeds	due	to	genital	tract	trauma	which	is	known	to	be	less	often	associated	
with	reduced	fibrinogen.
19;26
	The	observational	group	had	higher	laboratory	fibrinogen	and	Fibtem	
levels	at	study	entry	as	dictated	by	the	study	design.	Despite	this,	PT	and	aPTTs	were	similar	
between	the	observational	and	randomised	groups.	This	supports	previous	observations	that	
fibrinogen	falls	earlier	than	other	coagulation	factors	during	PPH
17
	and	that	an	adequate	fibrinogen	
can	be	used	as	a	surrogate	for	normal	laboratory	haemostasis	during	PPH.		
The	women	who	were	not	randomised	had	better	outcomes	than	the	women	who	were	not.	This	is	
because	the	two	groups	were	stratified	by	Fibtem	A5	and	Clauss	fibrinogen	levels	which	are	known	
to	be	predictive	of	progression	of	PPH
19;27-29
.	The	difference	in	outcomes	between	the	two	groups	
does	not	allow	any	conclusions	to	be	drawn	on	whether	a	restrictive	use	of	FFP	based	on	Fibtem	A5,	
as	described	here,	is	an	appropriate	treatment	strategy.	
Guidelines	recommend	maintaining	PT	and	aPTT	<1.5	times	normal	and	fibrinogen	>2	g	L
-1
.
2;4;8
	The	
randomised		arm	of	this	study	showed	that	if	the	Fibtem	A5	was	>12	mm	or	the	Clauss	fibrinogen	>2	
g	L
-1
	infusion	of	fibrinogen	concentrate	did	not	affect	outcomes,	supporting	the	conclusion	that	a	
fibrinogen	of	2	g	L
-1
	(or	Fibtem	>12	mm)	is	adequate	for	haemostasis	during	PPH.
20
	In	the	cohort	of	
women	reported	here,	FFP	was	withheld	if	the	Fibtem	A5	remained	>15	mm,	or	a	fibrinogen	of	
about	3	g	L	
-1	
.
20
	Only	eight	women	subsequently	developed	laboratory	evidence	of	established	
haemostatic	failure.	In	all	of	these	cases	the	Fibtem	A5	was	≤15	mm	but	bleeding	stopped	soon	after	
enrolment	through	obstetric	intervention	indicating	that	bleeding	was	not	caused	primarily	by	
coagulopathy.	Therefore,	withholding	FFP	guided	by	Fibtem	did	not	result	in	clinically	significant	
haemostatic	impairment	because	bleeding	was	controlled	with	obstetric	intervention	in	all	cases.	
Twelve	women	received	FFP	and	it	is	not	possible	to	be	certain	whether	FFP	infusion	influenced	
outcomes	in	these	women.	In	9	cases	FFP	was	infused	when	the	bleeding	had	stopped	and	tests	of	
haemostasis	were	normal	therefore	giving	FFP	is	unlikely	to	have	influenced	outcomes.	FFP	infusion	
in	these	cases	may	have	been	influenced	by	human	factors	such	as	concern	about	the	risk	of	further	
bleeding	or	the	desire	not	to	waste	FFP	that	had	been	thawed.	The	study	involved	a	large	number	of	
investigators	and	these	factors	may	have	varied	between	individuals.		
None	of	the	40	women	with	a	total	blood	loss	>2500	mL	developed	laboratory	evidence	of	
established	haemostatic	failure	and	it	is	unlikely	that	fibrinogen	or	FFP	infusion	would	have	reduced	
bleeding.	Clinicians	would	not	have	known	the	results	of	laboratory	coagulation	tests	for	about	60	
minutes,	therefore,	early	knowledge	of	the	Fibtem	A5	appears	to	have	been	useful	in	managing	
blood	product	replacement,	even	in	women	with	massive	PPH.	If	a	strategy	of	empirical,	fixed-ratio	
FFP	had	been	used	some	of	these	women	would	have	been	exposed	to	FFP	because	73%	received	
RBCs.	These	findings	suggest	that	withholding	FFP	based	on	clinical	assessment	of	bleeding	and	the	
Fibtem	A5	is	unlikely	to	result	in	clinically	significant	haemostatic	impairment.	
None	of	the	10	women	admitted	to	level	3	care	had	a	Fibtem	≤15	mm	or	laboratory	tests	consistent	
with	established	haemostatic	failure,	although	4	received	FFP	and	1	cryoprecipitate.	It	is	unlikely	that	
a	more	liberal	use	of	FFP	would	have	improved	outcomes,	however,	it	is	not	possible	to	exclude	that	
giving	FFP	may	have	influenced	outcomes	unrelated	to	haemostasis,	for	example	development	of	
respiratory	complications.	Four	women	were	admitted	to	level	3	care	for	respiratory	distress	or	fluid	
overload,	3	had	received	FFP	and	one	had	not.	Some	of	the	women	had	received	large	volumes	of	
fluids,	although	this	did	not	lead	to	evidence	of	haemostatic	failure	in	any	case.	No	data	were	
collected	on	catecholamine	usage.	Careful	review	of	fluid	balance	is	an	important	part	of	the	
management	of	PPH.
4;8
	
The	605	women	reported	in	this	study	are	a	selected	cohort	because	women	with	ongoing	bleeding	
and	a	Fibtem	A5	≤15	mm	entered	the	randomised	study.	In	the	whole	OBS2	study	(the	cohort	
reported	here	and	the	randomised	women	combined)	26.8%	received	RBCs,	4.1%	received	≥4	units	
RBC	and	9.2%	had	total	blood	loss	>2500	mL.	In	our	previously	published,	unselected,	consecutive	
cohort	of	356	women	recruited	with	similar	inclusion	criteria,	29.7%	received	a	RBC	transfusion,	9%	
received	≥4	units	RBC	and	10.7%	had	a	bleed	of	>2500	mL
19
.	This	suggests	that	some	women	with	
larger	bleeds	were	not	recruited	into	the	study	compared	to	an	unselected	cohort	of	women	with	
PPH.	It	is	likely,	therefore,	that	a	higher	proportion	of	women	with	PPH	would	develop	a	
coagulopathy	than	reported	here	because	some	cases	of	severe	bleeding,	where	coagulopathy	may	
develop	rapidly,	appear	to	be	under-represented	in	this	study.		
Despite	these	limitations,	our	data	support	the	observation	that,	if	the	Fibtem	A5	is	maintained	or	
bleeding	has	stopped,	FFP	is	not	required	to	maintain	clinically	adequate	haemostasis,	as	previously	
reported.
14;15
	Restrictive	use	of	FFP,	guided	by	Fibtem,	is	not	standard	practice	and	many	guidelines	
recommend	empirical,	fixed-ratio	FFP	if	laboratory	results	are	not	available.
2;4;8
	The	challenge	facing	
clinicians	treating	PPH	is	that	they	do	not	have	timely	tests	of	coagulation	and,	to	treat	the	minority	
of	women	with	haemostatic	compromise,	women	with	normal	haemostasis	must	also	be	
treated.
6;7;9-11
	At	present	NICE	does	not	support	the	use	of	VE-POCTs	during	PPH	but	recommends	
studies	investigating	the	clinical	and	cost	effectiveness	of	this	technology.		This	is	an	appropriate	
assessment	of	available	data	and	our	study	further	highlights	the	need	for	larger	more	definitive	
studies.		
The	strengths	of	this	study	include	the	large	number	of	women	treated	on	a	standardised	
haemostasis	management	protocol.	There	was	good	compliance	with	the	protocol	despite	the	
involvement	of	large	numbers	of	clinicians,	with	varying	levels	of	experience,	at	multiple	sites	
suggesting	that	it	is	feasible	to	integrate	VE-POCT	into	the	management	of	PPH.	The	main	
weaknesses	are	that	the	study	is	observational	and	there	is	no	control	arm	of	women	who	received	
fixed-ratio	RBC:FFP	transfusion	for	comparison.	It	remains	possible	that	a	more	liberal	use	of	FFP,	as	
recommended	by	many	clinicians,
6;7;9;10
	may	have	prevented	some	women	developing	haemostatic	
impairment	and	entering	the	randomised	arm	of	the	study.	Some	critically	unwell	women	were	not	
recruited	because	clinicians	could	not	follow	trial	procedures	whilst	managing	these	challenging	
cases.	Whether	a	restrictive	use	of	FFP,	guided	by	VE-POCTs,	is	appropriate	for	these	women	is	
unknown	and	requires	future	study.		
Conclusion	
This	study	shows	that,	in	the	cohort	of	women	recruited,	a	restrictive	use	of	FFP	based	on	clinical	
observation	of	bleeding	and	Fibtem	A5	is	feasible	and	did	not	result	in	clinically	significant	
haemostatic	impairment.	Studies	that	recruit	women	with	all	severities	of	PPH	are	needed	to	
compare	the	clinical	and	cost	effectiveness	of	a	liberal,	empirical	use	of	FFP,	as	recommended	by	
current	guidelines,
2;4;8
	with	a	restrictive	use	of	FFP	and	early	fibrinogen	replacement	based	on	point-
of-care	testing.	
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Table	1.Baseline	maternal	characteristics	at	study	entry	by	cohort	
Variable	 Observational	cohort	
(n=605)	
Interventional	cohort	
(n=55)	
p-value	
Demographics	 	 	 	
Age	at	recruitment	(years)	Mean	(range)	 31.87	(18-46)	 32.1	(20-48)	 0.8	
Body	mass	index	at	booking	Mean	(sd)	 27.43	(6.29)	 25.91	(5.00)	 0.04	
Missing	 3	 1	 	
Previous	caesarean	section	N	(%)		 123	(20.3)	 18	(32.7)	 0.03	
Pre-eclampsia	during	this	pregnancy	N	(%)	 30	(5.0)	 8	(14.5)	 0.003	
Past	history	of	postpartum	haemorrhage	N	(%)	 59	(9.8)	 11	(20.0)	 0.02	
Delivery		 	 	 	
Onset	of	labour	N	(%)	 	 	 	
Spontaneous	 214	(35.4)	 18	(32.7)	 	
Induced	 224	(37.0)	 11	(20.0)	 0.004	
No	labour	 167	(27.6)	 26	(47.3)	 	
Multiple	gestation	N	(%)	 	 	 	
Singleton	 564	(93.2)	 49	(89.1)	 0.3	
Twins	 41	(6.8)	 6	(10.9)	 	
Reported	causes	of	postpartum	
haemorrhage*N	(%)	
	 	 	
Uterine	atony	 373	(61.7)	 39	(70.9)	 NA	
Surgical	bleeding	 207	(34.2)	 19	(34.5)	 	
Trauma	 174	(28.8)	 10	(18.2)	 	
Retained	placenta	 70	(11.6)	 6	(10.9)	 	
Placental	abruption	 23	(3.8)	 5	(9.1)	 	
Placenta	praevia		 38	(6.3)	 3	(5.5)	 	
Undiagnosed	placenta	accrete	 2	(0.3)	 1	(1.8)	 	
Mode	of	delivery
†
N	(%)	 	 	 	
Spontaneous	vaginal	 167	(27.6)	 13	(23.6)	 	
Instrumental	vaginal	 140	(23.1)	 7	(12.7)	 0.2	
Elective	caesarean	section	 132	(21.8)	 16	(29.1)	 	
Non-elective	caesarean	section	 166	(27.4)	 19	(34.5)	 	
	*	women	may	have	had	more	than	one	cause	of	bleeding,	†for	multiple	pregnancies,	the	most	invasive	mode	is	
taken,	NA	is	not	available	because	many	women	had	multiple	causes	of	bleeding	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Estimated	blood	loss	at	study	entry	(mL)									
Median	(25th	to	75th	centiles)	
1200	
(1000	to	1500)	
1450	
(1200	to	1800)	
	
0.002	
Haemostatic	tests	at	study	entry		
Median	(25th	to	75th	centiles)	
Haemoglobin	(g/L)	
	
	
107	(97	to	116)	
	
	
95	(86	to	108)	
	
	
<0.001	
Missing	
Fibtem	A5	(mm)	
Missing	
Clauss	Fibrinogen	(g/L)	
Missing						
Prothrombin	time	(s)	
Missing						
Activated	partial	thromboplastin	time	(s)	
Missing	
8	
19	(17	to	22.5)	
0	
4.0	(3.4	to	4.6)	
101	
10.8	(10.3	to	11.4)	
73	
25.0	(23.2	to	27.2)	
86	
0	
12	(9	to	14)	
0	
2.7	(2.4	to	3.3)	
4	
10.9	(10.2	to	12.0)	
1	
26.0	(22.8	to	30.0)	
7	
	
<0.001	
	
<0.001	
	
0.2	
	
0.2	
Table	2.	Study	outcomes	by	cohort	
Outcome	 Observational	
cohort	
(n=605)	
Interventional	
cohort	
(n=55)	
Blood	loss	
Blood	loss	after	study	entry	
Median	(25
th
	to	75
th
	centile)	
range	
Missing	
300		
(50-545)	
0	to	3800	
	12
*
	
896		
(500	to	1400)	
0	to	3600	
Total	blood	loss		
Median	(25th	to	75th	centile)	
range	
1500		
(1300	to	2000)	
650	to	5500	
2480		
(1982.5	to	3260)	
1028	to	5300	
Total	blood	loss	>2500	mL	N	(%)	 40	(6.6)	 26	(47.3)	
Transfusion	
Red	blood	cells	
Median	(25th	to	75th	centile)	units	
Number	transfused	N	(%)	
Number	transfused	4	or	more	units	N	(%)	
	
0	(0	to	0)	
141	(23.3)	
11	(1.8)	
	
2	(0	to	4)	
35	(63.6)	
16	(29.1)	
Fresh	frozen	plasma	
Median	(25th	to	75th	centile)	units	
Number	transfused	N	(%)	
	
0	(0	to	0	
12	(2.0)	
	
0	(0	to	1)	
14	(25.5)	
Cryoprecipitate		
Median	(25th	to	75th	centile)	units	
Number	transfused	N	(%)	
	
0	(0	to	0	
2	(0.3)	
	
0	(0	to	0)	
2	(3.6)	
Platelets	
Median	(25th	to	75th	centile)	units	
Number	transfused	N	(%)	
	
0	(0	to	0)	
1	(0.2)	
	
0	(0	to	0)	
7	(12.7)	
Cell	salvage	
Median	(25th	to	75th	centile)	
Number	transfused	N	(%)	
	
0	(0	to	0)	
27	(4.5)	
	
0	(0	to	0)	
3	(5.5)	
Obstetric	interventions	to	control	bleeding	
Number	of	uterotonic	doses	used		
Median	(25th	to	75th	centile)	
range		
	
2	(2	to	4)		
1	to	9	
	
3	(5	to	6)		
2	to	8	
Number	of	invasive	procedures	
Median	(25th	to	75th	centile)	
range		
	
Women	requiring	no	invasive	procedure	N	(%)	
Women	requiring	one	invasive	procedure	N	(%)	
Women	requiring	two	invasive	procedures	N	(%)	
Women	requiring	three	invasive	procedures	N	(%)	
Women	requiring	four	invasive	procedures	N	(%)	
Women	requiring	five	invasive	procedures	N	(%)	
	
Type	of	invasive	procedure†	
Hysterectomy	N	(%)	
Intra-uterine	balloon	catheter	N	(%)	
Uterine	compression	sutures	N	(%)	
Manual	removal	of	placenta	N	(%)	
Perineal	repair	N	(%)	
Vaginal	pack	N	(%)	
Examination	under	anaesthetic	N	(%)	
Laparotomy	N	(%)	
	
0	(0	to	1)	
0	to	5	
	
322	(53.2)	
173	(28.6)	
80	(13.2)	
21	(3.5)	
7	(1.2)	
2	(0.3)	
	
1	(0.2)	
45	(7.4)	
9	(1.5)	
57	(9.4)	
154	(25.5)	
80	(13.2)	
62	(10.2)	
2	(0.3)	
7	(1.2)	
	
1	(0	to	2)	
0	to	4	
	
22	(40.0)	
10	(18.2)	
11	(20.0)	
11	(20.0)	
1	(1.8)	
0	(0)	
	
(0)	
15	(27.3)	
2	(3.6)	
4	(7.2)	
11	(20)	
15	(27.3)	
18	(32.7)	
4	(7.3)	
0	(0)	
Outcome	 Observational	
cohort	
(n=605)	
Interventional	
cohort	
(n=55)	
Bimanual	compression	N	(%)	
Other	not	stated	N	(%)	
Interventional	radiology	N	(%)	
Uterine	artery	ligation	N	(%)	
14	(2.3)	
0	(0)	
0	(0)	
0	(0)	
0	(0)	
0	(0)	
Use	of	tranexamic	acid	
												Number	treated	N	(%)	
	
182	(30.1)	
	
55	(100%)	
Hospital	stay	and	Level	2	and	3	care	
Level	3	care	N	(%)	
Length	of	stay	of	women	admitted	to	level	3	care	(hrs)		
											Median	(25
th
	to	75
th
	centile)		
10	(1.7)	
	
21	(9.25	to	25.25)	
4	(7.3)	
	
2,	4,	18,	168
‡
.	
Level	2	care	N	(%)	
Length	of	stay	of	women	admitted	to	level	2	care	(hrs)		
											Median	(25
th
	to	75
th
	centile)	
																518	(85.6)							
	
10	(6	to18)	
51	(94)		
	
17	(10	to	26)	
Length	of	hospital	stay	(days)		
										Median	(25
th
	to	75
th
	centile)	
	
2	(2	to	4)	
	
3	(2	to	4)	
*Total	blood	loss	was	reported	to	be	less	than	blood	loss	at	study	entry	and	so	cases	were	excluded	
from	this	analysis,	†women	may	have	had	more	than	one	invasive	procedure,	
‡	
number	of	hours	for	
each	woman	is	given	due	to	low	number	of	cases.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
